Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15108MR)

This product GTTS-WQ15108MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15108MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1453MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ10706MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4782MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ11512MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ9964MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ725MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ5202MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ10236MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW